LAUSANNE, Switzerland, May 27, 2022 — Gnubiotics Sciences, a biotech company pioneering immunomodulatory glycopeptides, today announced that results from its GLAAD technology program in Colorectal Cancer (CRC) will be presented in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7, 2022 in Chicago, Illinois (USA).
The poster entitled Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model will be presented by Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer, on June 5.
“We are thrilled to present compelling pre-clinical efficacy data in colorectal cancer. These findings nicely complement previous work in melanoma presented earlier this year at AACR. Our Glycopeptides with tumor-associated Antigen and Adjuvant Delivery (GLAAD) technology is designed to drive and boost immune responses directed against various solid tumors and we are excited that the technology continues to deliver promising preclinical data, paving the way for future clinical development. With our collaborators at the University of Zurich we demonstrated that our proprietary glycopeptide candidates were capable to control tumor growth either alone or in combination with existing treatment. We are convinced that glycan-based strategies like our GLAAD approach bear great potential for safe and effective immunotherapies and respond to the urgent need for new modalities for non-responding patients that are otherwise left with few alternative treatments,” stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer.
Abstract Title: Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model.
Abstract Number: 2565
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
The Poster will also be made available for browsing on the first day of the 2022 ASCO Annual Meeting. Viewers will have the possibility to e-mail questions and comments to the presenter.
About Gnubiotics Sciences SA
Gnubiotics Sciences SA is a Swiss-based biotech company focused on the identification, characterization, and development of glycopeptides assets to tackle immune and inflammatory diseases in humans. The company’s proprietary GLAAD molecules leverage years of research, manufacturing know-how and combine insights from the fields of glycoscience, microbiology and immunology to create a novel approach to treating cancer. Beyond oncology, the company has initiated and led the development and commercialization of various glycopeptide-based assets across various applications.
Glycopeptides are the foundation of Gnubiotics’ GLAAD molecules. GLAAD relies on glycopeptides as providers of antigenicity and adjuvanticity to the immune system. Gnubiotics’ GLAAD candidates are made of a range of glycans uniquely bound to peptides and can act directly on immune cells and modulate the microbiome. Combined, these modes of action influence the immune system responses which opens new ways to address areas where the immune system play a role, including inflammatory and infectious diseases.